InsidersTradesSigma
Total declarations
Companies
▲ Purchases (2 ops.)
▼ Sales (0 ops.)
Insider track record
ExecutiveDisclosed buys
2
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Explore the detailed record of transactions filed by Hrynkow Sharon Hemond, Directeur Scientifique. Director active across 2 companies, notably Cyclo Therapeutics, Inc.. In total, 2 disclosures have been published. Split: 2 buys · 0 sell. Total volume traded: €10k. Activity tracked since 2 December 2021. The latest transaction was filed on 20 December 2022 (Acquisition). Regulator: SEC (Form 4). All data is free.
Companies and markets linked to Hrynkow Sharon Hemond
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations2 total
5,000 shares@ US$1.13100.0% of flowCommon StockSEC:0001683168-22-008580:0
Canonical exit: 20 Mar 2023 (T+90)
1,000 shares@ US$4.98100.0% of flowCommon StockSEC:0001437749-21-027716:0
Canonical exit: 2 Mar 2022 (T+90)
2 of 2 declarations
About Hrynkow Sharon Hemond
Hrynkow Sharon Hemond is the Chief Scientific Officer of Cyclo Therapeutics, Inc. She is responsible for leading the company's research and development initiatives. Her role involves overseeing scientific projects and ensuring that research objectives are met. With extensive expertise in her field, she plays a key role in the innovation of the company's products.
